Chemotherapy in metastatic renal cell cancer

World Journal of Urology

Volumn 23, Issue 3, 2005, Pages 175-179

  Lilleby, Wolfgang ^a   Fosså, Sophie D ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chemotherapy; Cytokines; Drug resistance; Renal cell cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; DRUG RESISTANCE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG RESISTANCE, NEOPLASM; HUMANS; KIDNEY NEOPLASMS;

EID: 23744431849     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00345-004-0469-x     Document Type: Article

References (52)

1. Motzer RJ, Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163:408-417 1:STN:280:DC%2BD3c7ht1Wluw%3D%3D
2. Mickisch G, Bier,H, Bergler W, et al. (1999) P-170 glycoprotein, glutathione and associated enzymes in relation to chemoresistance of primary human renal cell carcinomas. Urol Int 45:170-176
3. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162 1:CAS:528:DyaE28XlvV2qs70%3D
4. Mickisch GH (1994) Chemoresistance of renal cell carcinoma: 1986-1994. World J Urol 12:214-223
5. Ford JM, Yang JM, Hait WN (1996) P-glycoprotein-mediated multidrug resistance: Experimental and clinical strategies for its reversal. Cancer Treat Res 87:3-38 1:CAS:528:DyaK2sXitFWnsbs%3D
6. Anderson ME (1998) Glutathione: An overview of biosynthesis and modulation. Chem Biol Interact 111/112:1-14
7. Mickisch GH, Noordzij MA, Van der Gaast A et al. (1995) Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma. J Cancer Res Clin Oncol 121 [Suppl 3]:R11-16
8. Braybrooke JP, Vallis KA, Houlbrook S et al. (2000) Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine. Cancer Chemother Pharmacol 46:27-34 1:CAS:528:DC%2BD3cXjvVKisrk%3D
9. Gnarra JR, Tory K, Weng Y et al. (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90
10. Bindra RS, Vasselli JR, Stearman R et al. (2002) VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 62:3014-3019 12036906
11. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 95:7987-7992 1:CAS:528:DyaK1cXks1SlsrY%3D
12. Hockel M, Vaupel P (2001) Biological consequences of tumor hypoxia. Semin Oncol 28:36-41 1:STN:280:DC%2BD3MzivVSgsw%3D%3D
13. Fossa SD, Kramar A, Droz JP (1994) Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 30A:1310-1314 1:STN:280:ByqD1M3jvVY%3D
14. Thiesse P, Ollivier L, Di Stefano-Louineau D et al. (1997) Response rate accuracy in oncology trials: Reasons for interobserver variability. Groupe Francais d'Immunotherapie of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 15:3507-3514 1:STN:280:DyaK1c%2FlslSktQ%3D%3D
15. Erasmus JJ, Gladish GW, Broemeling L et al. (2003) Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: Implications for assessment of tumor response. J Clin Oncol 21:2574-2582
16. Duffaud F, Therasse P (2000) New guidelines to evaluate the response to treatment in solid tumors (in French). Bull Cancer 87:881-886 1:STN:280:DC%2BD3M7ktVyntQ%3D%3D
17. Therasse P (2002) Measuring the clinical response. What does it mean? Eur J Cancer 38:1817-1823 1:STN:280:DC%2BD38vkslyntw%3D%3D
18. Hrushesky WJ, Von Roemeling R, Lanning RM et al. (1990) Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol 8:1504-1513
19. Yagoda A, Abi-Rached B, Petrylak D (1995) Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 22:42-60 1:STN:280:ByqC2MfovFw%3D
20. Fossa SD, Droz JP, Pavone-Macaluso MM et al. (1992) Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group. Eur J Cancer 28A:878-880 1:STN:280:By2A1MbgvVc%3D
21. Marcus SG, Choyke PL, Reiter R et al. (1993) Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 150:463-466 1:STN:280:ByyA3MnjvFU%3D
22. Ryan CW, Vogelzang NJ, Stadler WM (2002) A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. Cancer 94:2602-2609 1:CAS:528:DC%2BD38XktF2gu7g%3D
23. Stadler WM, Huo D, George C et al. (2003) Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 170:1141-1145 1:CAS:528:DC%2BD3sXovFOhsrw%3D
24. Bennouna J, Delva R, Gomez F et al. (2003) A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma. Oncology 64:25-27 1:CAS:528:DC%2BD38XptFaqtbs%3D
25. Haas NB, Giantonio BJ, Litwin S et al. (2003) Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: A phase II trial of the Fox Chase Network. Cancer 98:1837-1841 1:CAS:528:DC%2BD3sXpt1artrw%3D
26. Oevermann K, Buer J, Hoffmann R et al. (2000) Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 83:583-587 1:CAS:528:DC%2BD3cXmvVCgsro%3D
27. Fizazi K, Rolland F, Chevreau C et al. (2003) A phase II study of irinotecan in patients with advanced renal cell carcinoma. Cancer 98:61-65 1:CAS:528:DC%2BD3sXlslagtbs%3D
28. Stadler WM, Kuzel T, Roth B et al. (1997) Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394-3398 1:CAS:528:DyaK2sXnsVensb0%3D
29. De Mulder PH, Weissbach L, Jakse G et al. (1996) Gemcitabine: A phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 37:491-495 8599874
30. Porta C, Zimatore M, Imarisio I, et al. (2004) Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: Final results of a single-institution Phase II study. Cancer 100:2132-2138 1:CAS:528:DC%2BD2cXksF2rs7w%3D
31. Rini BI, Vogelzang NJ, Dumas MC et al. (2000) Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 18:2419-2426
32. Escudier B, Chevreau C, Lasset C et al. (1999) Cytokines in metastatic renal cell carcinoma: Is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d'Immunotherape. J Clin Oncol 17:2039-2043 1:CAS:528:DyaK1MXkvVSmtb0%3D
33. Bruntsch U, Heinrich B, Kaye SB et al. (1994) Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group. Eur J Cancer 30A:1064-1067 1:STN:280:ByqA1czgt1M%3D
34. Park DK, Ryan CW, Dolan ME et al. (2002) A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. Cancer Chemother Pharmacol 50:160-162 1:CAS:528:DC%2BD38Xls12ns70%3D
35. Townsley CA, Chi K, Ernst DS et al. (2003) Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: A trial of the National Cancer Institute of Canada-Clinical Trials Group, J Clin Oncol 21:1524-1529
36. Berg WJ, Schwartz L, Yu R et al. (2001) Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma. Invest New Drugs 19:317-320 10.1023/A:1010609810517
37. Yang JC, Sherry RM, Steinberg SM et al. (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127-3132 10.1200/JCO.2003.02.122
38. Atzpodien J, Kirchner H, Siebels M et al. (2004) Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: A prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22:1188-1194 10.1200/JCO.2004.06.155
39. Bleumer I, Oosterwijk E, De Mulder P et al. (2003) Immunotherapy for renal cell carcinoma. Eur Urol 44:65-75 1:CAS:528:DC%2BD3sXmt1WntLs%3D
40. Fossa SD, Mickisch GH, De Mulder PH et al. (2004) Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. Cancer 101:533-540 1:CAS:528:DC%2BD2cXmslChsrY%3D
41. Motzer RJ, Murphy BA, Bacik J et al. (2000) Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18:2972-2980
42. Sunkara U, Walczak JR, Summerson L et al. (2004) A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma. J Interferon Cytokine Res 24:37-41
43. Bacoyiannis C, Dimopoulos MA, Kalofonos HP et al. (2002) Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials. Oncology 63:130-138 1:STN:280:DC%2BD38vps1ahtQ%3D%3D
44. Negrier S, Caty A, Lesimple T et al. (2000) Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d'Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 18:4009-4015 1:CAS:528:DC%2BD3MXktFegtg%3D%3D
45. Neri B, Cini G, Doni L et al. (2002) Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: A multicenter phase II study. Br J Cancer 87:497-501 1:CAS:528:DC%2BD38Xmt12qtbY%3D
46. Vaishampayan U, Flaherty L, Du W et al. (2001) Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma. Cancer 92:519-523 1:CAS:528:DC%2BD3MXmsVyjt7Y%3D
47. Schwartsmann G, Medina De Cunha F, Silveira LA et al. (1991) Phase II trial of vinblastine plus nifedipine (VN) in patients with advanced renal cell carcinoma (RCC). Brazilian Oncology Trials Group. Ann Oncol 2:443 1:STN:280:By2C3MfmvVI%3D
48. Gershanovich MM, Moiseyenko VM, Vorobjev AV et al. (1997) High-dose toremifene in advanced renal-cell carcinoma. Cancer Chemother Pharmacol 39:547-551 1:CAS:528:DyaK2sXis1ajt70%3D
49. Liu JH, Yang MH, Fan FS et al. (2001) Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study. Urology 57:650-654 1:STN:280:DC%2BD3M3ms1Wqsg%3D%3D
50. Amarto RJ, Perez C, Pagliaro L (2002) Irofulven, a novel inhibitor of DNA synthesis in metastatic renal cell cancer. Invest New Drugs 20:413-417 12448659
51. Gez E, Rubinov R, Gaitani D et al. (2002) Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: A prospective phase II study: The experience of Rambam and Lin Medical Centers 1996-2000. Cancer 95:1644-1649 1:CAS:528:DC%2BD38XosFWltLY%3D
52. Chaouche M, Pasturaud AL, Kamioner D et al. (2000) Oxaliplatin, 5-fluorouracil, and folinic acid (Folfox) in patients with metastatic renal cell carcinoma: Results of a pilot study. Am J Clin Oncol 23:288-289 1:STN:280:DC%2BD3czhsVSgug%3D%3D